CMG Pharmaceutical

At a glance

CMG Pharmaceutical filed 36 disclosures in the last 12 months, including 3 5% holder, 2 insider, 1 contract and 1 issuance. The most recent key filing was on Oct 14: A major holder's stake fell from 5.14% to 0.69% (conversion/exercise).

Revenue for 2025 was ₩105B, up 6.2% on 2024. It made an operating loss of ₩3.7B. Debt was 52% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩53.8B and operating loss of ₩5.9B.

The 2025 annual report lists 206 employees with an average tenure of 5 years and average pay of ₩62.8M, #849 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩71.2M each on average. It paid no cash dividend for 2025. (주)차바이오텍 and related parties held 24.27% at year end.

Of 2 recent 5%+ holder reports, 0 raised and 2 cut a stake; the largest stake reported was 24.23% on Oct 12.

From the 2025 annual report

Staff: 206 (108 men, 98 women), of whom 7 on fixed-term contracts. Total pay for the year: ₩12.9B. Directors and auditors: 7, paid ₩498.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)차바이오텍 holds 24.27%; with 0 related parties the group holds 24.27% of common shares at year end (from 25.84% at the start of the year).

Auditor: 삼도회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports